Substance / Medication

Cannabidiol

Overview

Active Ingredient
cannabidiol
RxNorm CUI
2045371

Indications

EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.

Labeler: Jazz Pharmaceuticals, Inc.Updated: 2025-07-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

11 5.4 [see Description () and Warnings and Precautions ()]. EPIDIOLEX is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Unlocking the potential: Cannabidiol (CBD) as a promising anti-tumor agent.
Duan Shuqin, Liu Mingyu, An Zhechao et al. · Phytomedicine · 2026
PMID: 41494497Meta-Analysis
The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.
Candeloro Bruno Moreira, de Oliveira Camila M, Gimenez Fabiana Veronez Martelato et al. · Int J Mol Sci · 2025
PMID: 41373770Meta-AnalysisFull text (PMC)
Nanoformulated cannabidiol for skin disorders: A GRADE-based systematic review of therapeutic evidence and efficacy.
Ahmed Bakr, Kaur Simrandeep, Naryal Srishti et al. · Eur J Pharm Biopharm · 2025
PMID: 40518055Meta-Analysis
Therapeutic potential of cannabidiol in oral disorders: A systematic review of clinical evidence.
de Abreu Lukas Mendes, Biancardi Mariel Ruivo, Di Benedetto Michele et al. · J Am Dent Assoc · 2025
PMID: 41062198Meta-Analysis
Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: A systematic review.
Saranti Anna, Dragoumi Pinelopi, Pavlogiannis Konstantinos et al. · Seizure · 2025
PMID: 41135306Meta-Analysis
The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review.
Shafie Mahan, Ing Kevin, Rostam-Abadi Yasna et al. · Addict Biol · 2025
PMID: 40415392Meta-AnalysisFull text (PMC)
Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature.
Esmaeli Mojtaba, Dehabadi Maryam Dehghanpour, Khaleghi Ali Asghar · BMC Cancer · 2025
PMID: 40275168Meta-AnalysisFull text (PMC)
Targeting Gastrointestinal Cancers with Cannabidiol: Mechanisms, Challenges, and Therapeutic Implications.
Esmaeli Mojtaba, Dehghanpour Dehabadi Maryam · Med Oncol · 2025
PMID: 40461928Meta-Analysis
The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.
Aderinto Nicholas, Olatunji Gbolahan, Kokori Emmanuel et al. · Eur J Med Res · 2024
PMID: 38500226Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cannabidiol (substance)
SNOMED CT
96223000
UMLS CUI
C0006863
RxNorm CUI
2045371
Labeler
Jazz Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.